Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

BACKGROUND: Patients with COVID-19 pneumonia can have increased inflammation and elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab, a high-affinity anti-IL-6 receptor antibody, might improve the outcome of patients with moderate-to-severe COVID-19 pneumoni...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598187/
https://www.ncbi.nlm.nih.gov/pubmed/34812424
http://dx.doi.org/10.1016/S2665-9913(21)00315-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598187/
https://www.ncbi.nlm.nih.gov/pubmed/34812424
http://dx.doi.org/10.1016/S2665-9913(21)00315-5

Ejemplares similares